

B1

50 ⁵ SU The present invention relates to peptides which influence the release of gonadotropins by the pituitary gland in mammals, including humans. More particularly, the present invention is directed to peptides which when administered acutely to mammals exhibit increased potency in releasing gonadotropins, which subsequently cause the release of the steroid hormones, progesterone, testosterone and estrogens.

Mark B. ⁶ The pituitary gland is attached to a stalk to the region in the base of the brain known as the hypothalamus and has two principal lobes, the anterior lobe and the posterior lobe. The posterior lobe of the pituitary gland stores and passes onto the general circulation system two hormones manufactured in the hypothalamus, i.e., vaso-pressin and oxytocin. The anterior lobe of the pituitary gland secretes a number of hormones, which are complex protein or glycoprotein molecules, that travel through the blood stream to various organs and which, in turn, stimulate the secretion into the blood stream of other hormones from the peripheral organs. In particular, follicle stimulating hormone (FSH) and luteinizing hormone (LH), sometimes referred to as gonadotropins or gonadotropic hormones, are released by the pituitary gland. These hormones, in combination, regulate the functioning of the gonads to produce testosterone in the testes and progesterone and estrogen in the ovaries, and also regulate the production and maturation of gametes.

The release of a hormone by the anterior lobe

2

of the pituitary gland usually requires a prior release of another class of hormones produced by the hypothal-

*B*amus. Such a hypothalamic hormone acts as a factor that triggers the release of the gonadotropic hormones, particularly luteinizing hormone (LH). The particular hypothalamic hormone which acts as a releasing factor for the gonadotropins LH and FSH is referred to herein as LRF, wherein RF stands for "releasing factor" and L signifies that one hormone released is LH. LRF has been isolated, identified and synthesized.

It has been demonstrated that some female mammals who have no ovulatory cycle and who show no pituitary or ovarian defect begin to secrete normal amounts of the gonadotropins LH and FSH after the administration of LRF. Such administration of LRF is suitable for the treatment of those cases of infertility where the functional defect resides in the hypothalamus. Ovulation can also be induced in female mammals by the administration of LRF; however, the dosage level of LRF required to influence ovulation may sometimes be high. Recent reports have also indicated that the administration of large and frequent dosages of LRF actually inhibit gonadal function in female and male rats by desensitization of the pituitary and gonads and subsequent disruption of the hormonal network. For this reason, LRF and analogs of LRF which are more potent than LRF to promote release of LH have been investigated for potential use as a contraceptive. The principal disadvantage to the use of these peptides as a potential contraceptive is, of course, the requirement for large and frequent dosages. It


-2-

would be desirable to provide peptides which are many times more potent than LRF in promoting the secretion of LH.

Accordingly, it is a principal object of the present invention to provide peptides which exhibit a very 5 high potency to cause the release of gonadotropins in mammals, including humans. Another object of the present invention is to provide such potent peptides which influence the release of steroids by the gonads of male and female mammals, including humans, and which have properties 10 which favorably affect their administration. A further object of the present invention is to provide peptides which have a more potent effect than LRF on the reproduction processes of mammals, including humans. These and other objects of the present invention will become more apparent 15 from the following detailed description.

Generally, in accordance with the present invention, LRF agonists have been synthesized which have an enhanced potency to cause the secretion of gonadotropins by the pituitary gland of mammals, including humans, and which 20 peptides also can cause inhibition of the reproductive functions in both males and females, such as delay of puberty, interruption of pregnancy, decrease in sexual organ weights and steroid production, and disrupted spermogenesis. The peptides of the present invention are characterized by the 25 substitution of (im-Bz1) D-His in the 6-position of LRF or an LRF analog.

LRF has been characterized as a decapeptide having the following structure:



Peptides are compounds which contain two or 5 more amino acids in which the carboxyl group of one acid is linked to the amino group of the other acid. The formula for LRF, as represented above, is in accordance with conventional representation of peptides where the amino group appears to the left and the carboxyl group 10 to the right. The position of the amino groups is identified by numbering the amino groups from left to right. In the case of LRF, the hydroxyl portion of the carboxyl group at the right-hand end has been replaced with an amino group (NH_2), to give an amide function. The abbreviations for the individual amino acid groups above are 15 conventional and are based on the trivial name of the amino acid: where p-Glu is pyroglutamic acid, His is histidine, Trp is tryptophan, Ser is serine, Tyr is tyrosine, Gly is glycine, Leu is Leucine, Arg is arginine and Pro is proline. Except for glycine, amino acid residues in the 20 peptides of the invention should be understood to be of the L-configuration unless noted otherwise.

It is known that the substitution of a D-amino acid (for example D-Trp) for Gly in the 6-position of the 25 LRF decapeptide provides a peptide material having from about 10 to 30 times greater potency than does LRF to effect the release of luteinizing hormone and other gonadotropins by

the pituitary gland of mammals. The releasing effect is obtained when the substituted peptide is introduced into the blood stream of a mammalian. The desired peptides are not significantly different in their hydrophilicity 5 from LRF, whereas other potent LRF analogs are significantly less hydrophilic, and this will provide opportunities for administration in various ways including those most suitable for peptides having a longer duration of effect.

In accordance with the present invention, peptides 10 have been synthesized which are highly potent to release gonadotropins and are represented by the following formula:

{ p-Glu-His-Trp-Ser-Tyr-D-His(im-Bzl)-Leu-Arg-R

wherein R is selected from the group consisting of Pro-Gly-

NH₂ and Pro-NH-CH₂-CH₃. D-His(im-Bzl) refers to imidazole

15 benzyl D-histidine wherein the benzyl group is attached to

a one of the nitrogen atoms in the ^{imidazole} ring of the histidine residue.

The peptides of the present invention having 20 D-His(im-Bzl) in the 6-position have greatly enhanced potency compared to other known LRF analogs which have been reported earlier, for example in U.S. Patents Nos. 3,896,104, 3,972,859 and 4,034,082. The enhanced potency of these LRF agonists and the fact that they are substantially more hydrophilic than other analogs renders them of significant 25 value in treating both male and female infertility and also in the inhibition of reproductive functions in both males and females as a result of long-term administration.

The peptides of the present invention are synthesized by a solid phase technique. The synthesis is preferably conducted in a stepwise manner on a chloromethylated resin when R is Pro-NH-CH₂-CH₃ and on a benzhydrylamine or a methyl-benzhydrylamine resin when R is Pro-Gly-NH₂.
5 However, a chloromethylated resin may also be used when R is Pro-Gly-NH₂ because aminolysis of the glycine benzyl ester can be achieved using ammonia. The resin is composed of fine beads (20 $\frac{1}{4}$ 70 microns in diameter) of a synthetic resin prepared by copolymerization of styrene with 1 to 2 percent divinylbenzene. For a chloromethylated resin, the benzene rings in the resin are chloromethylated in a Friedel-Crafts reaction with chloromethyl ether and stannic chloride, and the chlorine introduced is a reactive benzyl chloride. The 10 Friedel-Crafts reaction is continued until the resin contains 0.5 to 2 millimoles of chlorine per gram of resin. The benzhydrylamine resin is prepared in accordance with the teaching of U.S. Patent No. 4,072,688 issued February 7, 1976 to Max S. Amoss et al. More recently, a paramethyl-BHA has 15 been used, which may be obtained as generally described in U.S. Patent No. 4,072,688 with the exception that p-toluolyl chloride is used instead of benzyl chloride in the Friedel-Crafts step. Mild conditions during HF cleavage can be used with such a resin, and as a result, a purer peptide is obtained than the equivalent one made on regular BHA.
20
25

The reagents used are hereinbelow first listed by their chemical name and their common abbreviation.

A peptide wherein R is Pro-NH-CH₂-CH₃ or Pro-Gly-NH₂, may be prepared, for example by esterifying the triethylammonium salt of α -amino protected Pro or Gly onto the chloromethylated resin by refluxing in ethanol for about 5 48 hours. Also possible is the use of α -amino protected Pro, potassium or cesium salts in dimethylformamide (DMF) or in dimethylsulfoxide (DMS), at temperatures ranging from 40° to 80°C. Further possible is the use of the α -amino protected Pro dissolved in DMF in combination with 10 the chloromethylated resin in the presence of KF. After deprotection of the α -amino N-terminus and neutralization, the stepwise addition of N-protected amino acids is effected as generally taught in Monahan, et al. Biochemistry (1963) Volume 12, P. 4616-4620. The N $^{\alpha}$ groups may be protected by 15 t-butoxycarbonyl (BOC), and the side chain of Arg may be protected with p-toluenesulfonyl (Tos). Benzyl ester (OBz1) may be used as a side chain protecting group for Ser and Tyr. 2-6 dichlorobenzyl may be used as the side chain protecting group for Tyr; and Tos, dinitrophenyl (Dnp) or BOC can be used as the side chain protecting group for His. pGlu may 20 be introduced, for example, as benzyloxycarbonyl (Z) protected amino acid, or without any protection.

Such a method provides the fully protected peptidoresin, and the fully protected peptide is removed 25 from the resin support in a suitable manner, e.g., using ammonia or by aminolysis employing dimethylamine, methylamine, ethylamine, n-propylamine, i-propylamine, butylamine,

-8-

iso-butylamine, pentylamine or phenethylamine to yield a fully protected alkyl amide intermediate. As one example, cleavage of the peptide from the resin may be performed by stirring the peptidoresin (...Pro-O-CH₂-resin) over-
5 night in distilled ethylamine at 0°C. in a pressure bottle. As another example, the peptidoresin (...⁷Pro-Gly-O-CH₂-resin) may be treated for several days in dry methanol which is kept saturated with NH₃ by bubbling gaseous ammonia therethrough. After removal of excess ethylamine or
10 methanolic ammonia by distillation under nitrogen or vacuum, the resin, suspended in methanol, is removed from the slurry by filtration. The resin is further washed successively with dimethylformamide (DMF), methanol, and a mixture of DMF and methanol. The recovered solution of cleaved, protected
15 peptide is evaporated to dryness on a rotary vacuum evaporator at room temperature. The peptide is taken in a minimum amount of methanol to dissolve the peptide. The solution is added dropwise with stirring to a 200-times volume excess of dry ether. A flocculent precipitate appears which is recovered
20 by filtration or centrifugation. The recovered precipitate is dried to provide the intermediate which is considered part of the invention.

The intermediates of the invention may be represented as:

$\text{P} \text{ x}^1\text{-p-Glu-His(x}^2\text{)-Trp-Ser(x}^3\text{)-Tyr(x}^4\text{)-D-His(im-Bz1)}$

5 $\text{C} \text{-Leu-Arg(x}^5\text{)-Pro-x}^6$ wherein: x^1 is either hydrogen or an
60 α -amino protecting group of the type known to be useful in
the art in the stepwise synthesis of polypeptides. Among
the classes of α -amino protecting groups covered by x^1 are (1)
10 acyl-type protecting groups, such as formyl, trifluoroacetyl,
phthalyl, Tos, benzensulfonyl, nitrophenylsulfenyl, trityl-
sulfenyl, o -nitrophenoxyacetyl, chloroacetyl, acetyl and
 y -chlorobutyryl; (2) aromatic urethan-type protecting groups,
e.g., benzyloxycarbonyl and substituted benzyloxycarbonyl,
such as p -chlorobenzyloxycarbonyl, p -nitrobenzyloxycarbonyl,
 p -bromobenzyloxycarbonyl and p -methoxybenzyloxycarbonyl; (3)
15 aliphatic urethan protecting groups, such as BOC, diisopropyl-
methoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl and
allyloxycarbonyl; (4) cycloalkyl urethan-type protecting
groups, such as cyclopentyloxycarbonyl, adamantlyloxycarbonyl
and cyclohexyloxycarbonyl; (5) thiourethan-type protecting
20 groups, such as phenylthiocarbonyl; (6) alkyl-type protecting
groups, such as triphenylmethyl (trityl) and benzyl; (7) trialkyl-
silane groups, such as trimethylsilane. The preferred α -amino
protecting group is BOC.

25 x² is a protecting group for the imidazole nitrogen atom selected from the group consisting of Tos, benzyl, trityl, 2,2,2-trifluoro-1-benzyloxycarbonylaminoethyl, 2,2,2,-trifluoro-1-tert-butyloxycarbonylaminoethyl and 2,4-dinitrothiophenyl.

x^3 is a protecting group for the alcoholic hydroxyl group of Ser and is selected from the group consisting of acetyl, benzoyl, tetrahydropyranyl, tert-butyl, trityl, benzyl and 2,6-dichlorobenzyl and preferably 5 is benzyl.

x^4 is a protecting group for the phenolic hydroxyl group of Tyr selected from the group consisting of tetrahydropyranyl, tert-butyl, trityl, benzyl, benzyloxycarbonyl, 4-bromobenzyloxycarbonyl and 2,6-dichlorobenzyl.

10 x^5 is a protecting group for the nitrogen atoms of Arg and is selected from the group consisting of nitro, Tos, benzyloxycarbonyl, adamantyloxycarbonyl; and BOC; or is hydrogen which means there are no protecting groups on the side chain nitrogen atoms of arginine.

15 x^6 is selected from dimethylamine, alkylamine of 1 to 5 carbon atoms, phenethylamine, $O-CH_2-[resin support]$ or $Gly-O-CH_2-[resin support]$ or $Gly-NH-[resin support]$.

20 The criterion for selecting side chain protecting groups for x^2-x^5 are that the protecting group must be stable to the reagent under the reaction conditions selected for removing the α -amino protecting group at each step of the synthesis, the protecting group must not be split off under coupling conditions and the protecting group must be removable upon completion of the synthesis of the desired amino acid 25 sequence under reaction conditions that will not alter the peptide chain.

When the x^6 group is $-O-CH_2-$ [resin support] or
Gly- $O-CH_2-$ [resin support], what is represented is the
ester moiety of one of the many functional groups of the
polystyrene resin support. When the x^6 group is Gly- NH_2
5 [resin support], an amide bond connects Gly to benzhydryl-
amine resin or to methyl benzhydrylamine resin.

For the preparation of a peptide wherein R is
Pro-Gly- NH_2 on a benzhydrylamine resin, N-termini and
side chain protecting groups as generally defined above
10 are used for the synthesis. Coupling of the Gly residue
is carried out for 1 to 5 hours in methylenechloride
(CH_2Cl_2), dimethylformamide (DMF) or mixtures thereof,
using a 2-5 fold excess of BOC-protected amino acid and
dicyclohexylcarbodiimide (DCC) activating reagent. The
15 first residue is attached to the benzhydrylamine resin by
an amide bond. The coupling reaction throughout the
synthesis is monitored by a ninhydrin test, as reported by
Kaiser et al. Anal. Biochem. 34 (1970) 595.

Deblocking is effected by a 20-minute treatment
20 in TFA containing 5 percent 1,2-ethanedithiol, followed
by neutralization with triethylamine (Et_3N) in DMF or
methylene chloride. Numerous washes with MeOH and CH_2Cl_2
follow each step. The individual amino acid residues are
added sequentially to complete the peptide chain.

25 Deprotection of the peptides and/or cleavage
of the peptide from a benzhydrylamine resin or paramethyl-
BHA resin may take place at $0^{\circ}C$. with hydrofluoric acid
(HF) or other suitable reagent. Anisole or some
other appropriate scavenger, e.g., methyl anisole or

thioanisole, is preferably added to the peptide prior to treatment with HF. After the removal of HF, under vacuum, the cleaved, deprotected peptide is treated with ether, filtered, extracted in dilute acetic acid, separated from 5 the resin by filtration and lyophilized.

Purification of the peptide may be effected by ion exchange chromatography on a carboxyl methyl cellulose (CMC) column, followed by partition chromatography on a gel filtration column using the elution system: n-butanol; 10 acetic acid; water (4:1:5; volume ratio). Sephadex G 25 may be the partition chromatography column packing, and other cation exchange, such as CM-Sephadex or counter- current distribution, can also be used for the purification.

The peptides are used at a level effective to 15 promote ovulation in female mammals and can also be used for other pharmaceutical purposes for which LRF has heretofore been employed. Because the potency of the peptides of the invention is about 12 and 217 times that of LRF (see Table I, hereinafter) the dosage may be determined for each 20 application on the basis of such a ratio, taking other factors such as the subject of administration into considera- tion. For example, a suitable dosage may be within the range of about 5 ng. (nanograms) to 10 μ g. daily, per kilogram of body weight.

25 The peptide can be administered to mammals intra- venously, subcutaneously, intramuscularly, intranasally, vaginally, orally or sublingually. The effective dosage will vary with the form of administration and the particular species of mammal to be treated. Oral administration may be in either 30 solid or liquid form.

Because the peptides of the invention exhibit hydrophilicity comparable to that of LRF, higher concentrations can be prepared in aqueous or saline solutions which provide significant advantages in 5 administration over the other superagonist analogs reported thus far. A most important advantage lies in the fact that such an aqueous peptide solution can be administered intranasally.

The peptide may also be prepared and administered 10 in the form of a pharmaceutically acceptable nontoxic salt, such as an acid-addition salt, or an appropriate metal complex, e.g., with zinc, iron or the like. Illustrative of pharmaceutically acceptable non-toxic salts of peptides are hydrochloride, hydrobromide, sulfate, phosphate, maleate, 15 acetate, citrate, benzoate, succinate, malate, ascorbate, and the like.

DE The following Examples further illustrate various features of the invention but are intended to in no way limit the scope of the invention which is defined in the appended 20 claims.

CL EXAMPLE I

P [im-Bzl D-His⁶]-LRF having the following formula
is prepared by the solid phase synthesis: p-Glu-His-Trp-Ser- \textcircled{O}
Tyr-D-His(im-Bzl)-Leu-Arg-Pro-Gly-NH₂.

25 A paramethyl benzhydrylamine resin is used, and BOC-protected Gly is coupled to the resin over a 2-hour period in CH₂Cl₂ using a 3-fold excess of the BOC reagent and dicyclohexylcarbodiimide (DCC) as an activating reagent. This

attaches the glycine residue to the benzhydrylamine residue by an amide bond.

Following the coupling of each amino acid residue, washing, deblocking and coupling of the next amino acid residue is carried out in accordance with the following schedule using an automated machine and beginning with about 5 grams of resin:

	<u>Step</u>	<u>Reagents and Operations</u>	<u>Mix Times</u> <u>Min.</u>
	1	CH ₂ Cl ₂ wash 80 ml (2 times)	3
10	2	Methanol (MeOH) wash 30 ml (2 times)	3
	3	CH ₂ Cl ₂ wash 80 ml. (3 times)	3
	4	50 percent trifluoroacetic acid (TFA) plus 5 percent 1,2 - ethanedithiol in CH ₂ Cl ₂ 70 ml. (2 times)	10
15	5	CH ₂ Cl ₂ wash 80 ml. (2 times)	3
	6	Triethylamine (Et ₃ N) 12.5 percent in 70 ml. of CH ₂ Cl ₂ (2 times)	5
	7	MeOH wash 40 ml. (2 times)	2
	8	CH ₂ Cl ₂ wash 80 ml. (3 times)	3
20	9	BOC-amino acid (10 mmoles) in 30 ml. of either DMF or CH ₂ Cl ₂ , depending upon the solubility of the particular protected amino acid, (1 time) plus dicyclohexylcarbodiimide (DCC) (10 mmoles) in CH ₂ Cl ₂	30-300
	10	MeOH wash 40 ml. (2 times)	3
25	11	Et ₃ N 12.5 percent in CH ₂ Cl ₂ 70 ml. (1 time)	3
	12	MeOH wash 30 ml. (2 times)	3
	13	CH ₂ Cl ₂ wash 80 ml. (2 times)	3

10/30X
P After step 13, an aliquot is taken for a ninhydrin test: if the test is negative, go back to step 1 for coupling

of the next amino acid; if the test is positive or slightly positive, go back and repeat steps 9 through 13.

The above schedule is used for coupling of each of the amino acids of the peptide of the invention after the 5 first amino acid has been attached. N^{α} BOC protection is used for each of the remaining amino acids throughout the synthesis. The side chain of Arg is protected with Tos. OBzl is used as a side chain protecting group for the hydroxyl group of Ser, and 2-6 dichlorobenzyl is used as the 10 side chain protecting group for the hydroxyl group of Tyr. p-Toluenesulfonyl (Tos) is used as the side chain protecting group for His at the 2-position, but D-His(im-Bzl) does not require side-chain protection. pGlu is introduced as the benzyloxycarbonyl (Z) protected amino acid or as plain 15 p-Glu. The following amino acids, which have low solubility in CH_2Cl_2 , are coupled using DMF: BOC-Arg(Tos); BOC-Trp; Z-pGlu or pGlu; and D-His(im-Bzl).

The cleavage of the peptide from the resin and complete deprotection of the side chains with the exception 20 of (im-Bzl) of D-His⁶ takes place very readily at 0°C. with 2% hydrofluoric acid (HF). Anisole is added as a scavenger prior to HF treatment. After the removal of HF under vacuum, the resin is extracted with 0.1% acetic acid, and the washings are lyophilized to provide a crude peptide 25 powder.

Purification of the peptide is then effected by ion exchange chromatography on carboxymethyl cellulose

(Whatman CM 32, using a step gradient of 0.125M NH₄OAc) followed by partition chromatography in a gel filtration column using the elution system: n-Butanol; Acetic acid; Water (4:1:5--volume ratio).

5 [D-His⁶(im-Bzl)]-LRF is judged to be homogeneous using thin layer chromatography with several different solvent systems and using reversed-phase high pressure liquid chromatography as generally taught in Rivier, "Use of Trialkyl Ammonium Phosphate (TAAP)
37

10 Buffers in Reverse Phase HPLC for High Resolution and High Recovery of Peptides and Proteins", Journal of Liquid Chromatography, 1(3), 343-366 (1978) and employing an aqueous triethylammonium phosphate buffer plus acetonitrile as the solvent system. Amino acid analysis of the resultant, purified peptide is consistent with the formula for the prepared structure, showing substantially integer values for each amino acid in the chain. Nuclear magnetic resonance spectra is also consistent and shows the presence of the benzyl group. The optical rotation is measured on a
15 photoelectric polarimeter $[\alpha]_D^{22} = -26.0^\circ$ (c=1, 1% acetic acid).
20

EXAMPLE II

25 The LRF analog [D-His⁶(im-Bzl), Pro⁹-NET]-LRF is synthesized by solid phase technique in a stepwise manner on a chloromethylated resin prepared by the copolymerization of styrene with about 1% divinylbenzene.

The triethylammonium salt of BOC-protected Pro is esterified onto the chloromethylated resin by refluxing in ethanol for about 48 hours. After deprotection and neutralization, the BOC-derivative of the next amino acid, 5 Arg, and each successive amino acid, is added in accordance with the procedure set forth in Example I.

The fully protected peptide is removed from the resin support by aminolysis employing ethylamine to yield the fully protected alkyl amide intermediate.

10 Cleavage of the peptide is performed by stirring the resin overnight in distilled ethylamine at 0°C. in a pressure bottle. After removal of excess ethylamine by distillation under vacuum, the resin, suspended in methanol, is removed from the slurry by filtration. The 15 resin is further washed successively with DMF, methanol, and a mixture of DMF and methanol. The recovered solution of cleaved, protected peptide is evaporated to dryness on a rotary vacuum evaporator at room temperature. Using a minimum amount of methanol to dissolve the peptide, the 20 solution is added dropwise to a 250-times volume excess of dry ether with stirring. A flocculent precipitate appears and is recovered by centrifugation. The recovered precipitate is dried to provide the intermediate, which is then completely deprotected using HF as earlier described.

25 Purification of the peptide is effected by ion exchange chromatography on a CMC column, followed by partition chromatography using the elution system: n-butanol; acetic acid; water (4:1:5--volume ratio). The partition chromatography column is Sephadex G 25.

[D-His⁶(im-Bzl)Pro⁹NET]-LRF is judged to be homogeneous using thin layer chromatography and several different solvent systems, as well as by using reversed-phase high pressure liquid chromatography and an aqueous 5 triethylammonium phosphate solution plus acetonitrile. Amino acid analysis of the resultant, purified peptide is consistent with the formula for the prepared structure, showing substantially integer-values for each amino acid in the chain. Nuclear magnetic resonance spectra is also 10 consistent and shows the presence of the benzyl group.

The optical rotation is measured on a photoelectric polarimeter $[\alpha]_D^{22} = -33.9^\circ$ (c=1, 1% acetic acid).

The peptides prepared in the foregoing Example I are assayed in vitro using a four-day-old primary culture 15 of dispersed rat pituitary cells and compared with LRF. The levels of LH secreted over a 4-hour period in response to the application of peptides are assayed by specific radioimmunoassay for rat LH. The results of testing are expressed in Table I herebelow:

20

TABLE I

<u>TREATMENT</u>	<u>NANOGRAMS OF LH SECRETED</u>
Control	612
0.1 nM LRF	1255
0.3 nM LRF	1767
1.0 nM LRF	2167
3.0 nM LRF	2867
25	
0.003 nM Ex. I	885
0.01 nM Ex. "	1345
0.03 nM Ex. "	2150
0.1 nM Ex. "	2225
30	
0.3 nM Ex. "	2667

P The treatment procedure is repeated using the peptide prepared in Example II and the results set forth in Table II are obtained:

TABLE II

	<u>TREATMENT</u>	<u>NANOGRAMS OF LH SECRETED</u>
5	Control	500
	0.3 nM LRF	631
	1.0 nM LRF	1001
	3.0 nM LRF	1496
10	0.003 nM Ex. II	895
	0.01 nM Ex. II	1256
	0.03 nM Ex. II	2008
15		

*P*The peptide prepared in Example I has a relative potency, compared to LRF, of 12(5.8-24) $\frac{1}{M}$ the confidence limits being shown in the parentheses. For the peptide prepared in Example II, the relative potency is 217(57-952). Based upon these tests, it can be seen that [D-His⁶(im-Bzl)]-LRF has a potency about 12 times that of LRF and that [D-His⁶(im-Bzl), Pro⁹-NET]-LRF has a potency of more than 200 times that of LRF.

The effectiveness of the peptide compositions prepared in Examples I and II is also tested in vivo, and the relative agonistic potencies of peptides determined in the in vitro assays reported above correlate well with the potencies obtained from in vivo tests. Comparison of the results shows that both peptide compositions are very significantly more potent than LRF when tested in vivo.

Based upon the foregoing, the peptides of the invention can be used to regulate fertility in male and female animals and human beings. High, frequent administrations of these peptides will inhibit fertility by blocking ovulation, including premature luteolysis and terminating pregnancy in females and in inhibiting spermatogenesis in males. Lower, intermittent administrations can restore fertility in those infertile states caused by LRF deficiency and can also allow timing of ovulation in normal females. The peptides can also be employed to reduce levels of sex steroids, and thus they can be used in the management of subjects with sex hormone dependent neoplasms. As earlier mentioned, the peptides can be administered by intravenous, subcutaneous, sublingual, oral, intravaginal, intranasal or rectal routes. The high water solubility of these peptides permits higher concentrations to be dissolved in physiologic solutions.

Although the invention has been described with regard to its preferred embodiments, it should be understood that changes and modifications as would be obvious to one having the ordinary skill in this art ^{may be made} ~~without departing~~ from the scope of the invention which is set forth in the claims which are appended hereto.

Various features of the invention are emphasized in the claims which follow.